Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer

Objective: Panel-based sequencing is widely used to measure tumor mutational burden (TMB) in clinical trials and is ready to enter routine diagnostics. However, cut-off points to distinguish “TMB-high” from “TMB-low” tumors are not consistent and the clinical implications of TMB in predicting respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jinchul, Kim, Binnari, Kang, So Young, Heo, You Jeong, Park, Se Hoon, Kim, Seung Tae, Kang, Won Ki, Lee, Jeeyun, Kim, Kyoung-Mee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082319/
https://www.ncbi.nlm.nih.gov/pubmed/32232003
http://dx.doi.org/10.3389/fonc.2020.00314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082319/
https://www.ncbi.nlm.nih.gov/pubmed/32232003
http://dx.doi.org/10.3389/fonc.2020.00314

Ejemplares similares